Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Veracyte Expands Into Urologic Cancer Testing By Acquiring Decipher For $600M

Executive Summary

With the addition of Decipher, Veracyte now offers tests for seven of the 10 most common types of cancer in the US.

You may also be interested in...



Veracyte Continues Cancer IVD Expansion By Acquiring HalioDx For $318M

The deal is Veracyte’s second major acquisition in cancer diagnostics in 2021 after agreeing to acquire Decipher Biosciences in March.

Dealmaking Quarterly Statistics, Q1 2021: Boston Scientific, Roche Start The Year With Billion-Dollar-Plus Acquisitions

During the first quarter, medical device company mergers and acquisition totalled $10.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $5bn.

Veracyte, J&J Launch NOBLE Trial For Lung Cancer Detection

The 9,000-patient clinical study will identify genomic and other differences in lung cancer development and progression among patients with lung nodules detected by computed tomography.

Topics

Related Companies

UsernamePublicRestriction

Register

MT143648

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel